Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus

Inclusion Criteria: * Patients aged ≥18 of either sex with the clinical diagnosis of oral lichen planus. * Patients with a PGA score of ≥3 (moderate and severe oral LP). * Patients who are willing to give informed written consent. Exclusion Criteria: * Treatment with a systemic corticosteroid within the last 4 weeks. * Patients on immunosuppressive agents such as azathioprine, cyclosporine, and others within one month of recruitment. * Patients with a clinical history and any lesion distribution suspicious of a lichenoid drug eruption, and patients with other skin diseases. * Past or current history of any malignancy, including moderate to severe dysplasia of the oral mucosa on oral biopsy. * Severe active infection, including active tuberculosis, hepatitis B, or C infection * Patients with cytopenia (Hb \<9g/dl, leukocyte count \<4000/mm3, platelet count \<100,000/mm3) * The patient with a history of alcohol abuse. * Decreased liver or renal function (creatinine \> 2.0mg/dl, total bilirubin \> 2.5 mg/dl). * Severe acute infection, uncontrolled diabetes mellitus, congenital or acquired immunodeficiency, severe cardiac disease (NYHA grade IV), MI in the last four weeks, severe schizophrenia, or depression. * Patient with a history of hypersensitivity to topical Triamcinolone or Tofacitinib. * Pregnancy and lactation, women of childbearing age without effective contraception.